On September 10, CSPC PHARMA fell 3.3% in regular trading, trading at HK$8.79/share, with turnover of HK$227 million. The decline extends a multi-day pullback as global risk aversion continues to weigh on Hong Kong-listed pharmaceutical stocks.

On the news front, a broad global equity selloff has intensified in recent sessions, with major European indices opening lower and Japan-Korea markets posting consecutive declines. The resulting risk-off sentiment has spilled into the Hong Kong market, dragging down the healthcare sector. Peer stocks declined in tandem, with Hansoh Pharma down 2.13%, Hengrui Pharma down 2.66%, Fosun Pharma down 4.22%, and Sihuan Pharma down 3.87%, reflecting sector-wide pressure rather than company-specific weakness.

Adding to near-term sentiment headwinds, Huatai-PineBridge Fund recently reduced its stake in CSPC PHARMA by approximately 39.12 million shares at an average price of around HK$9.75 per share, lowering its holding from 5.27% to 4.93%. The institutional trimming may have amplified selling pressure. Notably, the company's fundamentals remain supported by a flurry of recent pipeline milestones, including clinical approvals for SYH9102 and a rotigotine long-acting injection, as well as multiple investment banks maintaining buy ratings with target prices in the HK$11.2–14 range.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)